Hepatitis C virus RNA assays: current and emerging technologies and their clinical applications

References

• Alter HJ, Seeff LB. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin. Liver Dis.20(1), 17–35 (2000).
   PubMed Web of Science ®Google Scholar
• McHutchison JG, Lawitz EJ, Shiffman ML et al. Peginterferon α-2b or α-2a with ribavirin for treatment of hepatitis C infection. N. Engl. J. Med.361(6), 580–593 (2009).
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Berg T, Moeller B et al. Expert opinion on the treatment of patients with chronic hepatitis C. J. Viral Hepat.16(2), 75–90 (2009).
   PubMed Web of Science ®Google Scholar
• Rossignol J, Elfert A, El-Gohary Y, Keeffe E. Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin. Gastroenterology136(3), 856–862 (2009).
   PubMed Web of Science ®Google Scholar
• Eroglu C, Pinarbasi E. Hepatitis C virus: genome organization, viral proteins and implications in disease pathogenesis. Turk. J. Biol.24, 253–269 (2000).
   Google Scholar
• Le Guillou-Guillemette H, Vallet S, Gaudy-Graffin C et al. Genetic diversity of the hepatitis C virus: impact and issues in the antiviral therapy. World J. Gastroenterol.13(17), 2416–2426 (2007).
   PubMed Web of Science ®Google Scholar
• Zein NN. Clinical significance of hepatitis C virus genotypes. Clin. Microbiol. Rev.13(2), 223–235 (2000).
   PubMed Web of Science ®Google Scholar
• Scott JD, Gretch DR. Molecular diagnostics of hepatitis C virus infection: a systematic review. JAMA297(7), 724–732 (2007).
   PubMed Web of Science ®Google Scholar
• Poynard T, Imbert-Bismut F, Munteanu M et al. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp. Hepatol.3(1), 8 (2004).
   PubMedGoogle Scholar
• Richter SS. Laboratory assays for diagnosis and management of hepatitis C virus infection. J. Clin. Microbiol.40(12), 4407–4412 (2002).
   PubMed Web of Science ®Google Scholar
• Mederacke I, Wedemeyer H, Ciesek S et al. Performance and clinical utility of a novel fully automated quantitative HCV-core antigen assay. J. Clin. Virol.46(3), 210–215 (2009).
   PubMed Web of Science ®Google Scholar
• Medhi S, Potukuchi SK, Polipalli SK et al. Diagnostic utility of hepatitis C virus core antigen in hemodialysis patients. Clin. Biochem.41(7–8), 447–452 (2008).
   PubMedGoogle Scholar
• Scott JD, Gretch DR. Molecular diagnostics of hepatitis C virus infection: a systematic review. JAMA297(7), 724–732 (2007).
   PubMed Web of Science ®Google Scholar
• Saldanha J, Heath A, Aberham C et al. World Health Organization collaborative study to establish a replacement WHO international standard for hepatitis C virus RNA nucleic acid amplification technology assays. Vox Sang.88(3), 202–204 (2005).
   PubMed Web of Science ®Google Scholar
• Arrojo IP, Pareja MO, Orta MD et al. Detection of a healthy carrier of HCV with no evidence of antibodies for over four years. Transfusion43(7), 953–957 (2003).
   PubMedGoogle Scholar
• Ratcliff RM, Chang G, Kok T, Sloots TP. Molecular diagnosis of medical viruses. Curr. Issues Mol. Biol.9(2), 87–102 (2007).
   PubMed Web of Science ®Google Scholar
• Hill CS. Molecular diagnostic testing for infectious diseases using TMA technology. Expert Rev. Mol. Diagn.1(4), 445–455 (2001).
   PubMedGoogle Scholar
• Kadam JS, Gonzalez SA, Ahmed F, Menezes A, Jacobson IM. Prognostic significance of hepatitis C virus RNA detection by transcription-mediated amplification with negative polymerase chain reaction during therapy with peginterferon a and ribavirin. Dig. Dis. Sci.52(10), 2525–2530 (2007).
   PubMedGoogle Scholar
• Morishima C, Morgan TR, Everhart JE et al. Interpretation of positive transcription-mediated amplification test results from polymerase chain reaction-negative samples obtained after treatment of chronic hepatitis C. Hepatology48(5), 1412–1419 (2008).
   PubMedGoogle Scholar
• Urdea MS, Wuestehube LJ, Laurenson PM, Wilber JC. Hepatitis C – diagnosis and monitoring. Clin. Chem.43(8 Pt 2), 1507–1511 (1997).
   PubMedGoogle Scholar
• Litt MD, Simpson M, Recillas-Targa F, Prioleau MN, Felsenfeld G. Transitions in histone acetylation reveal boundaries of three separately regulated neighboring loci. EMBO J.20(9), 2224–2235 (2001).
   PubMedGoogle Scholar
• Matsuura K, Tanaka Y, Hasegawa I et al. Abbott RealTime hepatitis C virus (HCV) and Roche Cobas AmpliPrep/Cobas TaqMan HCV assays for prediction of sustained virological response to pegylated interferon and ribavirin in chronic hepatitis C patients. J. Clin. Microbiol.47(2), 385–389 (2009).
   PubMedGoogle Scholar
• Pyne MT, Konnick EQ, Phansalkar A, Hillyard DR. Evaluation of the Abbott investigational use only RealTime hepatitis C virus (HCV) assay and comparison to the Roche TaqMan HCV analyte-specific reagent assay. J. Clin. Microbiol.47(9), 2872–2878 (2009).
   PubMedGoogle Scholar
• Wasfy AI, Azzazy HM. Development of a real-time PCR assay for detection and quantification of hepatitis C virus RNA. Clin. Chem.55(6 Suppl.), A151 (2009).
   Google Scholar
• Nolte FS. Hepatitis C virus genotyping: clinical implications and methods. Mol. Diagn.6(4), 265–277 (2001).
   PubMedGoogle Scholar
• Halfon P, Trimoulet P, Bourliere M el al. Hepatitis C virus genotyping based on 5´ noncoding sequence analysis (Trugene). J. Clin. Microbiol.39(5), 1771–1773 (2001).
   PubMed Web of Science ®Google Scholar
• Podzorski RP. Molecular testing in the diagnosis and management of hepatitis C virus infection. Arch. Pathol. Lab. Med.126(3), 285–290 (2002).
   PubMedGoogle Scholar
• Ross RS, Viazov SO, Holtzer CD et al. Genotyping of hepatitis C virus isolates using CLIP sequencing. J. Clin. Microbiol.38(10), 3581–3584 (2000).
   PubMedGoogle Scholar
• Bouchardeau F, Cantaloube JF, Chevaliez S et al. Improvement of hepatitis C virus (HCV) genotype determination with the new version of the INNO-LiPA HCV assay. J. Clin. Microbiol.45(4), 1140–1145 (2007).
   PubMed Web of Science ®Google Scholar
• Zekri AR, El-Din HM, Bahnassy AA et al. TRUGENE sequencing versus INNO-LiPA for sub-genotyping of HCV genotype-4. J. Med. Virol.75(3), 412–420 (2005).
   PubMed Web of Science ®Google Scholar
• Davidson F, Simmonds P, Ferguson JC et al. Survey of major genotypes and subtypes of hepatitis C virus using RFLP of sequences amplified from the 5´ non-coding region. J. Gen. Virol.76, 1197–1204 (1995).
   PubMed Web of Science ®Google Scholar
• Cook L, Sullivan K, Krantz EM, Bagabag A, Jerome KR. Multiplex real-time reverse transcription-PCR assay for determination of hepatitis C virus genotypes. J. Clin. Microbiol.44(11), 4149–4156 (2006).
   PubMedGoogle Scholar
• Antonishyn NA, Ast VM, McDonald RR et al. Rapid genotyping of hepatitis C virus by primer-specific extension analysis. J. Clin. Microbiol.43(10), 5158–5163 (2005).
   PubMedGoogle Scholar
• Rho J, Ryu JS, Hur W et al. Hepatitis C virus (HCV) genotyping by annealing reverse transcription-PCR products with genotype-specific capture probes. J. Microbiol.46(1), 81–87 (2008).
   PubMedGoogle Scholar
• Azzazy HM, Mansour MM, Kazmierczak SC. Nanodiagnostics: a new frontier for clinical laboratory medicine. Clin. Chem.52(7), 1238–1246 (2006).
   PubMed Web of Science ®Google Scholar
• Jain KK. Nanodiagnostics: application of nanotechnology in molecular diagnostics. Expert Rev. Mol. Diagn.3(2), 153–161 (2003).
   PubMed Web of Science ®Google Scholar
• Jain KK. Nanotechnology in clinical laboratory diagnostics. Clin. Chim. Acta358(1–2), 37–54 (2005).
   PubMed Web of Science ®Google Scholar
• Azzazy HM, Mansour MM. In vitro diagnostic prospects of nanoparticles. Clin. Chim. Acta403(1–2), 1–8 (2009).
   PubMed Web of Science ®Google Scholar
• Gerion D, Chen F, Kannan B et al. Room-temperature single-nucleotide polymorphism and multiallele DNA detection using fluorescent nanocrystals and microarrays. Anal. Chem.75(18), 4766–4772 (2003).
   PubMed Web of Science ®Google Scholar
• Radwan SH, Azzazy HM. Gold nanoparticles for molecular diagnostics. Expert Rev. Mol. Diagn.9(5), 511–524 (2009).
   PubMed Web of Science ®Google Scholar
• Baptista P, Pereira E, Eaton P et al. Gold nanoparticles for the development of clinical diagnosis methods. Anal. Bioanal. Chem.391(3), 943–950 (2008).
   PubMed Web of Science ®Google Scholar
• Griffin J, Singh AK, Senapati D et al. Size- and distance-dependent nanoparticle surface-energy transfer (NSET) method for selective sensing of hepatitis C virus RNA. Chemistry15(2), 342–351 (2009).
   PubMed Web of Science ®Google Scholar
• Glynou K, Ioannou PC, Christopoulos TK, Syriopoulou V. Oligonucleotide-functionalized gold nanoparticles as probes in a dry-reagent strip biosensor for DNA analysis by hybridization. Anal. Chem.75(16), 4155–4160 (2003).
   PubMed Web of Science ®Google Scholar
• Wang H, Yang R, Yang L, Tan W. Nucleic acid conjugated nanomaterials for enhanced molecular recognition. ACS Nano3(9), 2451–2460 (2009).
   PubMedGoogle Scholar
• Gruner G. Carbon nanotube transistors for biosensing applications. Anal. Bioanal. Chem.384(2), 322–335 (2006).
   PubMedGoogle Scholar
• Wu Y, Phillips JA, Liu H, Yang R, Tan W. Carbon nanotubes protect DNA strands during cellular delivery. ACS Nano2(10), 2023–2028 (2008).
   PubMedGoogle Scholar
• Dastagir T, Forzani ES, Zhang R et al. Electrical detection of hepatitis C virus RNA on single wall carbon nanotube-field effect transistors. Analyst132(8), 738–740 (2007).
   PubMed Web of Science ®Google Scholar
• Hitzler WE, Runkel S. Routine HCV PCR screening of blood donations to identify early HCV infection in blood donors lacking antibodies to HCV. Transfusion41(3), 333–337 (2001).
   PubMedGoogle Scholar
• Forcic D, Zgorelec R, Kosutic-Gulija T et al. Screening of serologically negative plasma pools for hepatitis C virus by nucleic acid amplification testing in Croatia, 2001–2003. Transfus. Apher. Sci.33(2), 175–179 (2005).
   PubMedGoogle Scholar
• Stramer SL, Caglioti S, Strong DM. NAT of the United States and Canadian blood supply. Transfusion40(10), 1165–1168 (2000).
   PubMedGoogle Scholar
• Ghany MG, Strader DB, Thomas DL, Seeff LB. American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology49(4), 1335–1374 (2009).
   PubMed Web of Science ®Google Scholar
• McGovern BH, Birch CE, Bowen MJ et al. Improving the diagnosis of acute hepatitis C virus infection with expanded viral load criteria. Clin. Infect. Dis.49(7), 1051–1060 (2009).
   PubMed Web of Science ®Google Scholar
• Caruntu FA, Benea L. Acute hepatitis C virus infection: diagnosis, pathogenesis, treatment. J. Gastrointestin. Liver Dis.15(3), 249–256 (2006).
   PubMedGoogle Scholar
• Pawlotsky JM. Use and interpretation of virological tests for hepatitis C. Hepatology36(5 Suppl. 1), S65–S73 (2002).
   PubMedGoogle Scholar
• Alberti A, Boccato S, Vario A, Benvegnù L. Therapy of acute hepatitis C. Hepatology36(5 Suppl. 1), S195–S200 (2002).
   PubMed Web of Science ®Google Scholar
• Moller JM, Krarup HB. Diagnosis of acute hepatitis C: anti-HCV or HCV-RNA. Scand. J. Gastroenterol.38, 556–558 (2003).
   PubMed Web of Science ®Google Scholar
• Fabris P, Fleming VM, Giordani MT, Barnes E. Acute hepatitis C: clinical aspects, diagnosis, and outcome of acute HCV infection. Curr. Pharm. Des.14(17), 1661–1665 (2008).
   PubMedGoogle Scholar
• Brant LJ, Ramsay ME, Balogun MA et al. Diagnosis of acute hepatitis C virus infection and estimated incidence in low- and high-risk English populations. J. Viral Hepat.15(12), 871–877 (2008).
   PubMedGoogle Scholar
• Chevaliez S, Pawlotsky JM. Hepatitis C virus serologic and virologic tests and clinical diagnosis of HCV-related liver disease. Int. J. Med. Sci.3(2), 35–40 (2006).
   PubMedGoogle Scholar
• Carey W. Tests and screening strategies for the diagnosis of hepatitis C. Cleve. Clin. J. Med.70(Suppl.), 7–13 (2003).
   Google Scholar
• Lasser L, Langlet P. What is the optimal duration of therapy in patients with hepatitis C genotype 2 or 3 infection?: a review. Acta Gastroenterol. Belg.71(3), 298–302 (2008).
   PubMedGoogle Scholar
• Webster G, Barnes E, Brown D, Dusheiko G. HCV genotypes – role in pathogenesis of disease and response to therapy. Baillieres Best Pract. Res. Clin. Gastroenterol.14(2), 229–240 (2000).
   PubMed Web of Science ®Google Scholar
• Ueda T, Chung H, Kudo M et al. Prolonged PEG-IFN and RBV is effective in patients with HCV genotype 1 and high viral load who achieved virological response later than 24 weeks. Intervirology53(1), 55–59 (2010).
   PubMedGoogle Scholar
• Bochud PY, Cai T, Overbeck K et al. Hepatitis C Cohort Study Group. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. J. Hepatol.51(4), 655–666 (2009).
   PubMed Web of Science ®Google Scholar
• Raimondi S, Bruno S, Mondelli MU, Maisonneuve P. Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: a meta-analysis. J. Hepatol.50(6), 1142–1154 (2009).
   PubMed Web of Science ®Google Scholar
• Sarrazin C, Teuber G, Kokka R, Rabenau H, Zeuzem S. Detection of residual hepatitis C virus RNA by transcription-mediated amplification in patients with complete virologic response according to polymerase chain reaction-based assays. Hepatology32(4 Pt 1), 818–823 (2000).
   PubMed Web of Science ®Google Scholar
• Pawlotsky JM. More sensitive hepatitis C virus RNA detection: what for? J. Hepatol.52(6), 783–785 (2010).
   PubMedGoogle Scholar
• Idrees M. Development of an improved genotyping assay for the detection of hepatitis C virus genotypes and subtypes in Pakistan. J. Virol. Methods150(1–2), 50–56 (2008).
   PubMedGoogle Scholar
• Shawky SM, Bald D, Azzazy HM. Direct detection of unamplified hepatitis C virus RNA using unmodified gold nanoparticles. Clin. Biochem.43(13–14), 1163–1168 (2010).
   PubMed Web of Science ®Google Scholar
• Glaab WE, Skopek TR. A novel assay for allelic discrimination that combines the fluorogenic 5´ nuclease polymerase chain reaction (TaqMan) and mismatch amplification mutation assay. Mutat. Res.30(1), 1–12 (1999).
   Google Scholar
• Seden K, Back D, Khoo S. New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals. J. Antimicrob. Chemother.65(6), 1079–1085 (2010).
   PubMed Web of Science ®Google Scholar
• Mao X, Ma Y, Zhang A, Zhang L, Zeng L, Liu G. Disposable nucleic acid biosensors based on gold nanoparticle probes and lateral flow strip. Anal. Chem.81(4), 1660–1668 (2009).
   PubMed Web of Science ®Google Scholar